Content	Strength of recommendation	Level of evidence
1	The primary goal of dyslipidemia treatment is to lower LDL-C.	I	A
2	Non-HDL-C can be controlled as a secondary goal after achieving the targeted LDL-C concentration.	II	A
3	Appropriate statin administration should be considered for high-risk and very high-risk groups in order to meet the LDL-C target.	IIa	B
4	Statin should be considered to use for low-risk or moderate-risk groups when LDL-C level is not reduced to the target even after weeks and months of lifestyle modification.	IIa	B
5	Ezetimibe or bile acid sequestrants should be considered for patients with statin intolerance.	IIa	B
6	Combination with ezetimibe should be considered if LDL-C target is not achieved even after using maximum tolerable dose of statin	IIa	B
7	PCSK9 inhibitors may be considered to concurrent use for the very high-risk group if LDL-C target is not achieved even after using maximum tolerable dose of statin alone or with ezetimibe.	IIb	A
8	Bile acid sequestrants may be considered if LDL-C target is not achieved even after administering statin.	IIb	C
9	Combination of statin and nicotinic acid is not recommended to achieve the LDL-C target.	III	A
10	If the targeted level is not achieved even after using statin alone or with other agents in the very high-risk group, reducing LDL-C by 50% of the baseline concentration is recommended.	I	A
11	Administer statin immediately for patients with acute myocardial infarction regardless of the baseline LDL-C concentration.	I	A
12	For individuals with a triglyceride concentration of 500 mg/dL or higher, immediate drug therapy and lifestyle modification are important to prevent acute pancreatitis.	I	A
13	For individuals with a triglyceride concentration of 200–499 mg/dL, the primary treatment goal is to lower the LDL-C to the targeted level based on the calculated cardiovascular risk.	I	A
14	For individuals with a triglyceride concentration of 200–499 mg/dL, pharmacological therapy should be considered to lower triglyceride concentration after achieving the targeted LDL-C level if triglyceride concentration is >200 mg/dL with cardiovascular risk factors, or if non-HDL-C concentration is above the target.	IIa	B
15	If indicated, fibrates should be used to control triglyceride concentration.	I	B
16	If indicated, omega-3 fatty acids should be considered to control triglyceride concentration.	IIa	B
17	Combination drug therapy may be considered if targeted triglyceride level is not met after monotherapy.	IIb	C
18	The primary goal for low HDL cholesterolemia treatment is to control LDL-C to below the target.	I	A